Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Biolex Therapeutics

Request full access

Biolex Therapeutics developed therapeutic proteins and monoclonal antibodies that had been optimized to enhance their efficacy and potency

Pittsboro, United StatesFounded 1997Biotech & Life Sciences

About Biolex Therapeutics

Biolex Therapeutics was a biopharmaceutical firm established in 1997 in North Carolina's Research Triangle, which ultimately ceased operations and filed for Chapter 7 bankruptcy in July 2012. The company attracted significant venture capital, raising approximately $190 million from a consortium of investors that included Johnson & Johnson Development, Clarus Ventures, Intersouth Partners, and Polaris Venture Partners. Over its history, Biolex pursued growth through strategic acquisitions, purchasing Epicyte Pharmaceutical Inc. in 2004 to bolster its monoclonal antibody capabilities, and LemnaGene SA of France in 2005 to consolidate its core technology.

The company's core business revolved around its proprietary LEX System, a novel technology platform for developing and manufacturing complex therapeutic proteins and monoclonal antibodies. This system utilized a genetically transformed aquatic plant, Lemna (duckweed), as a host for producing these biologics, offering a potential solution for proteins that were difficult or costly to synthesize with traditional methods. Biolex's business model involved both advancing its internal product pipeline and forming strategic alliances with larger pharmaceutical companies, such as Centocor and Bayer HealthCare, to develop proteins for them. One of its key internally developed candidates was Locteron, a controlled-release interferon alpha-2b for treating Hepatitis C. Locteron was engineered to reduce common side effects like flu-like symptoms and depression associated with existing interferon treatments by offering a more gradual release and less frequent injections.

Despite its technology and partnerships, Biolex faced significant challenges. A planned IPO in 2008 was withdrawn due to the financial crisis. The competitive landscape for Hepatitis C treatments evolved rapidly, with a new generation of drugs threatening to make products like Locteron obsolete. In May 2012, Biolex sold its core LEX System technology and two preclinical product candidates to the Dutch pharmaceutical company Synthon. Shortly after, having exhausted its venture funding and facing $38 million in liabilities, the company laid off its top executives, including CEO Jan Turek, and filed for liquidation, bringing its 15-year run to an end.

Source: Dealroom company data

At a glance

Founded
1997
Headquarters
Pittsboro, United States
Sector
Biotech & Life Sciences

Biolex Therapeutics in the Pittsboro ecosystem

Live from Dealroom

The Biolex Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Polaris Partners
  • Mitsui Global Investment
  • Johnson & Johnson Development Corporation
  • Kitty Hawk Capital

Series B and later3 investors entered at this stage

  • Intersouth Partners
  • Quaker Bio Ventures
  • Investor Growth Capital
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States66.7%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Biolex Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biolex Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.